790667-54-8

Basic information

• Product Name: 1-BOC-4-(3-bromophenoxy)piperidine
• Synonyms: 1-BOC-4-(3-bromophenoxy)piperidine;t-Butyl 4-(3-bromophenoxy)piperidine-1-carboxylate;tert-Butyl 4-(3-broMophenoxy)piperidine-1-carboxylate;4-(3-Bromophenoxy)piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 790667-54-8
• Molecular Formula: C₁₆H₂₂BrNO₃
• Molecular Weight: 356.258
• Mol File: 790667-54-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-4-(3-bromophenoxy)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(3-bromophenoxy)piperidine(790667-54-8)
• EPA Substance Registry System: 1-BOC-4-(3-bromophenoxy)piperidine(790667-54-8)

Safety Data

• Hazardous Substances Data: 790667-54-8(Hazardous Substances Data)

Usage

General Description

1-BOC-4-(3-bromophenoxy)piperidine, also known as tert-butyl 4-(3-bromophenoxy)piperidine-1-carboxylate, is a brominated and oxygenated organic compound with a specific molecular formula C16H22BrNO4. Characterized by the presence of a piperidine ring, which contains a six-membered ring containing five carbon atoms and one nitrogen atom, this compound finds significant use in the pharmaceutical and chemical research industries. Its complexity and structure make it useful in the creation or synthesis of a diverse array of commercially relevant substances. However, little is available about its safety, toxicity, or environmental impact, underscoring the need for more comprehensive research and data on this compound.

Upstream product

• 591-20-8 3-Bromophenol 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 

Downstream Products

• 864136-41-4 4-[3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester 
• 1570178-49-2 propan-2-yl 4-{3-[5-(methylsulfonyl)-2,3-dihydro-1H-indol-1-yl]phenoxy}piperidine-1-carboxylate 
• 1251940-27-8 tert-butyl 4-{3-[5-(methylsulfonyl)-2,3-dihydro-1H-indol-1-yl]phenoxy}piperidine-1-carboxylate 
• 1595291-31-8 tert-butyl 5-(tert-butoxycarbonyl (2-(3-((1-tert-butoxycarbonyl)piperidin-4-yl)oxy)phenyl)pyrimidin-4-yl)amino-1H-indazole-1-carboxylate 
• 1595289-75-0 N-(2-(3-(piperidin-4-yloxy)phenyl)pyrimidin-4-yl)-1H-indazol-5-amine 

Relevant articles and documents

IN VIVO ENGINEERED CEREBLON PROTEIN

Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.

TREATMENT OF OCULAR DISORDERS

The invention provides methods of treatment of ocular disorders, including ocular disease with an angiogenic component. In certain embodiments, the treatment comprises administration of a ROCK2 inhibitor and an angiogenesis inhibitor. In certain embodiments, the ROCK2 inhibitor is ROCK2 selective. In certain embodiments, the angiogenesis inhibitor is a VEGF antagonist, for example, and VEGFR2 antibody.

Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists

GPR119 has emerged as an attractive target for anti-diabetic agents. We identified a structurally novel GPR119 agonist 22c that carries a 5-(methylsulfonyl)indoline motif as an early lead compound. To generate more potent compounds of this series, structural modifications were performed mainly to the central alkylene spacer. Installation of a carbonyl group and a methyl group on this spacer significantly enhanced agonistic activity, resulting in the identification of 2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propyl 7-fluoro-5-(methylsulfonyl)-2,3-dihydro-1H-indole-1-carboxylate (20). To further expand the chemical series of indoline-based GPR119 agonists, several heterocyclic core systems were introduced as surrogates of the carbamate spacer that mimic the presumed active conformation. This approach successfully produced an indolinylpyrimidine derivative 37, 5-(methylsulfonyl)-1-[6-({1-[3-(propan-2- yl)-1,2,4-oxadiazol-5-yl]piperidin-4-yl}oxy)pyrimidin-4-yl]-2, 3-dihydro-1H-indole, which has potent GPR119 agonist activity. In rat oral glucose tolerance tests, these two indoline-based compounds effectively lowered plasma glucose excursion and glucose-dependent insulin secretion after oral administration.